Cancer News and Research

Latest Cancer News and Research

Two laboratory methods for Drosophila Neurobiology featured in Cold Spring Harbor Protocols journal

Cold Spring Harbor Laboratory's Neurobiology of Drosophila course (http://meetings.cshl.edu/courses/c-dros10.shtml) has served as the training ground for a generation of scientists tackling these complex problems. A new laboratory manual based on the protocols and background information taught in the course promises to spread these techniques to a wider audience. Two of the methods from the manual are featured in the July issue of the journal Cold Spring Harbor Protocols.

2 Jul 2010

Research may provide key to understanding interplay between exercise, aging and neurogenesis

Stem cells in the brain remain dormant until called upon to divide and make more neurons. However, little has been known about the molecular guards that keep them quiet.

2 Jul 2010

InNexus Biotechnology, NCI amend Collaborative Agreement

InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.

2 Jul 2010

Genes can predict longevity with 77% accuracy: Study

In an analysis of genes of more than 1,000 centenarians, American researchers have come to the conclusion that genes play a large role in completing a century in life. The research team studied 1,055 Caucasians born between 1890 and 1910 and compared them with 1,267 people born later. They claim that there are signatures in the genetic makeup of these people that have a possible link with their longevity.

2 Jul 2010

GSK, Genmab amend ofatumumab agreement

GlaxoSmithKline and Genmab A/S announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.

2 Jul 2010

Scientists explain mechanism behind acute myeloid leukemia

New research by scientists at Cold Spring Harbor Laboratory (CSHL) has illuminated in fine detail one of the genetic paths that leads to a particularly aggressive form of leukemia.

2 Jul 2010

DARA BioSciences suspends $10M underwritten public offering

On May 17, 2010, DARA BioSciences, Inc. issued a press release announcing that it had commenced an underwritten public offering of $10 million of units comprised of shares of common stock and warrants. DARA has decided to indefinitely suspend the offering, effective immediately. Several important factors have influenced this decision.

2 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.

1 Jul 2010

Advanced Life Sciences prices securities offering

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has established the pricing terms of its proposed offering of units.

1 Jul 2010

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.

1 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

1 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Some of the first analyses on the impact of Medicare Part D, as well as new insights on drug adherence patterns by chronic disease patients, will be presented today and tomorrow at the 2010 Academy/Health Annual Meeting by several University of Maryland, Baltimore teams of pharmaceutical health services researchers.

1 Jul 2010

Cell Therapeutics to retire all Notes with maturity in 2010

Cell Therapeutics, Inc. today announced that it has deposited $39.3 million in cash as trust funds with U.S. Bank National Association, as the trustee of the outstanding 4% convertible senior subordinated notes, which is an amount sufficient to pay and discharge the entire amount due on the Notes, including accrued and unpaid interest.

1 Jul 2010

Ronin, Hcf-1 bind together to control gene program that stimulates growth of stem cells

Ronin, crucial to the self-renewal of embryonic stem cells, and a co-regulator called Hcf-1, binds to a small strand of DNA called a hyperconserved enhancer element to control a gene "program" that stimulates growth of the stem cells and may even play a role in cancer, said a group of researchers led by Baylor College of Medicine in a current report in the journal Genes and Development.

1 Jul 2010

USPTO grants Semafore method patent for PI3K inhibitors

Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.

1 Jul 2010

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

The Florida Biomedical Research Program has awarded $2 million in biomedical research grants to three scientists from the Florida campus of The Scripps Research Institute.

1 Jul 2010

Cancer News and Research

Latest Cancer News and Research

Two laboratory methods for Drosophila Neurobiology featured in Cold Spring Harbor Protocols journal

Research may provide key to understanding interplay between exercise, aging and neurogenesis

InNexus Biotechnology, NCI amend Collaborative Agreement

Genes can predict longevity with 77% accuracy: Study

GSK, Genmab amend ofatumumab agreement

Scientists explain mechanism behind acute myeloid leukemia

DARA BioSciences suspends $10M underwritten public offering

Advanced Cancer Therapeutics secures $10M in investments

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

Advanced Life Sciences prices securities offering

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

AstraZeneca announces new support program for patients on ARIMIDEX

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Cell Therapeutics to retire all Notes with maturity in 2010

Ronin, Hcf-1 bind together to control gene program that stimulates growth of stem cells

USPTO grants Semafore method patent for PI3K inhibitors

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in